ArticlemBio2022
Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M
Open access · goldAbstract read
In one paragraph
Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 37 citations in OpenAlex.
- Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Development of a Complementation Assay to Monitor Pan-Coronavirus 3C-like Protease Activity.Viruses · 2026Article
- Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants.JACS Au · 2026Article
- Computational design of 3C-like protease substrate peptide for modular detection of protease activity of coronavirus.Engineering in life sciences · 2026Article
- A Novel Fluorescence Polarization Binding Assay for the Main Protease (MACS pharmacology & translational science · 2025Article
- Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity.Journal of medicinal chemistry · 2025Article
- Characterization of an unusual SARS-CoV-2 main protease natural variant exhibiting resistance to nirmatrelvir and ensitrelvir.Communications biology · 2025Article
- Article
- Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease.Science advances · 2025Article
- Rapid luminescence-based screening method for SARS- CoV-2 inhibitors discovery.SLAS discovery : advancing life sciences R & D · 2025Article
- The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery.The Journal of biological chemistry · 2025Article
- High throughput screening for SARS-CoV-2 helicase inhibitors.SLAS discovery : advancing life sciences R & D · 2024Article
- SARS-CoV-2 MSLAS discovery : advancing life sciences R & D · 2024Article
- A high-throughput cell-based screening method for Zika virus protease inhibitor discovery.SLAS discovery : advancing life sciences R & D · 2024Article
- SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme.ACS medicinal chemistry letters · 2024Article
- Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.Emerging microbes & infections · 2023Article
- Cellular Assays for Dynamic Quantification of Deubiquitinase Activity and Inhibition.Journal of molecular biology · 2023Article
- A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases.Journal of virology · 2023Article
- Rapid resistance profiling of SARS-CoV-2 protease inhibitors.npj antimicrobials and resistance · 2023Article
- Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.Protein science : a publication of the Protein Society · 2023Article
Corrections and comments
- Update of
Authors and funding
17 authors at 3 institutions in 1 country.
Seyed Arad MoghadasiDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Morgan A EslerDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Yuka OtsukaDepartment of Molecular Medicine, Scripps Research, The Scripps Research Molecular Screening Center, Jupiter, Florida, USA.
Jordan T BeckerDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Sofia N MoraesDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Constance B AndersonDepartment of Medicinal Chemistry, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Srinivas ChamakuriCenter for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA.
Christopher BelicaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Chloe WickDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Daniel A HarkiMasonic Cancer Center, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Damian W YoungCenter for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA.
Louis ScampaviaDepartment of Molecular Medicine, Scripps Research, The Scripps Research Molecular Screening Center, Jupiter, Florida, USA.
Timothy P SpicerDepartment of Molecular Medicine, Scripps Research, The Scripps Research Molecular Screening Center, Jupiter, Florida, USA.
Ke ShiDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Hideki AiharaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
William L BrownDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.
Reuben S HarrisDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesotagrid.17635.36, Minneapolis, Minnesota, USA.ORCID 0000-0002-9034-9112
University of Minnesota · USScripps Research Institute · USBaylor College of Medicine · US
Funding
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2MPROJECT 3 – BIOLOGY OF DNA DEAMINASES IN CANCERP01CA234228 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Reuben S Harris · 2019 to 2026
$14.5MStructural studies of viral replication and invasionR35GM118047 · NIGMS · UNIVERSITY OF MINNESOTA · PI Hideki Aihara · 2016 to 2026
$6.3MAPOBEC3 Proteins in HIV RestrictionR37AI064046 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HARRIS, REUBEN S · 2015 to 2024
$4.2MMinnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2MPixel Array Detector for X-ray CrystallographyS10RR029205 · NCRR · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2010 to 2010
$1.8MIntegrated Acoustic Transfer System for HTS Library ManagementS10OD025279 · OD · SCRIPPS FLORIDA · PI SCAMPAVIA, LOUIS DANIEL · 2018 to 2018
$624kTandem Multi-modal Plate Readers for a High Throughput Screening platformS10OD030330 · OD · UNIVERSITY OF FLORIDA · PI SCAMPAVIA, LOUIS DANIEL · 2021 to 2021
$600kHTS Drug Discovery DispensersS10OD026857 · OD · SCRIPPS FLORIDA · PI SCAMPAVIA, LOUIS DANIEL · 2019 to 2019
$452kAPOBEC PROTEINS AND RIBOVIRAL RESTRICTIONF32AI147813 · NIAID · UNIVERSITY OF MINNESOTA · PI BECKER, JORDAN T · 2019 to 2021
$192kHoward Hughes Medical InstituteNCI NIH HHS P01 CA234228NCRR NIH HHS S10 RR029205NIAID NIH HHS F32 AI147813NIAID NIH HHS R37 AI064046NIAID NIH HHS T32 AI083196NIGMS NIH HHS P30 GM124165NIGMS NIH HHS R35 GM118047NIH HHS S10 OD025279NIH HHS S10 OD026857NIH HHS S10 OD030330
Abstract
The main protease, M
Indexed as
Antiviral AgentsCoronavirus 3C ProteasesProtease InhibitorsSARS-CoV-2Amino AcidsLuciferases, Firefly3C-like proteinase, SARS-CoV-2Amino AcidsAntiviral AgentsCoronavirus 3C ProteasesLuciferases, FireflyProtease Inhibitorscoronavirusgain-of-signal cell-based systemsmain protease (Mpro/3CLpro)SARS-CoV-2 (SARS2)viral protease inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.